Document is current
Any future updates will be listed below
-
Authors
Ureshino, Hiroshi
Ueshima, Taichi
Yamaguchi, Tomonori
Takashima, Miyuki
Sanuki, Yusuke
Ichinohe, Tatsuo
-
Funding
Funding for this research was provided by:
the Program of the network-type Joint Usage/Research Center for Radiation Disaster Medical Science of Hiroshima University, Nagasaki University, and Fukushima Medical University
Wakunaga Pharmaceutical Co., Ltd
- License Information
-
More Information
Article History
Received: 24 October 2024
Accepted: 14 April 2025
First Online: 8 May 2025
Declarations
:
: HU reports personal fees from Novartis. TU, TY, MT, and YS are full-time employees of Wakunaga Pharmaceutical Co., Ltd. TI has received speaker honoraria from Novartis and research funding from Chugai Pharmaceutical Co. and Wakunaga Pharmaceutical Co., Ltd.
: The experiments were conducted in accordance with protocols approved by the Wakunaga Pharmaceutical Company Institutional Animal Care and Use Committee (Permission No. 375) and conform to the Guide for the Care and Use of Laboratory Animals published by the United States National Institute of Health. The study adhered to ARRIVE guidelines.
